Name: Cash Ratio

Definition: The cash ratio measures a company's ability to pay off all of its current liabilities immediately using only its most liquid assets: cash and cash equivalents. Unlike the current ratio and quick ratio, it excludes accounts receivable and inventory, making it the most conservative measure of liquidity.

Interpretation:
• In '2021', TRVI's cash ratio was 2.89, indicating the company's ability to meet short-term obligations purely with cash. Industry average for Biotechnology: Pharmaceutical Preparations in '2021' stood at 3.01.
• In '2022', TRVI's cash ratio was 0.94, indicating the company's ability to meet short-term obligations purely with cash. The decline from '2021' may indicate some operational or financial challenges. Industry average for Biotechnology: Pharmaceutical Preparations in '2022' stood at 2.56. Industry average declined by 0.45 from previous year.
• In '2023', TRVI's cash ratio was 5.56, indicating the company's ability to meet short-term obligations purely with cash. The increase since '2022' reflects strengthening financial performance. Industry average for Biotechnology: Pharmaceutical Preparations in '2023' stood at 2.27. Industry average declined by 0.29 from previous year.
• In '2024', TRVI's cash ratio was 3.24, indicating the company's ability to meet short-term obligations purely with cash. The decline from '2023' may indicate some operational or financial challenges. Industry average for Biotechnology: Pharmaceutical Preparations in '2024' stood at 2.14. Industry average declined by 0.13 from previous year.
Overall, TRVI's cash ratio has been volatile but showed an upward trend over the past 4 years.

Formula: Cash Ratio = (Cash + Cash Equivalents) / Current Liabilities

Good Range: Generally, a cash ratio between 0.2 and 0.5 is considered healthy for most industries.